Novavax, Inc. NAVX stock traded higher on Wednesday.In an SEC filing, Novavax said, “We believe that our Biologics License Application (BLA) is approvable based on conversations with U.S. Food and Drug Administration (FDA), as of our Prescription Drug User Fee Act date on April 1 and through today.”The company said that it received formal communication from the FDA in the form of an information request for a post-marketing commitment to generate additional clinical data.Also Read: Despite Headwinds, Biotech ...